Who Paid My Doc
Hubert Franke
General Practice Wall, NJ Medical Doctor
NPI 1366416240 CMS profile 459060
1985 Highway 34, Unit A8, Wall, NJ 07719
General payments
$36
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Hubert Franke of Wall, NJ is reported in the CMS Open Payments database as having received $36 across 2 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 16th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $20 | 1 | |
| 2023 | General | $16 | 1 |
Beside peers
- Hubert Franke
- General Practice median
- Middle half of General Practice
- National median
In program year 2025, general payments to Hubert Franke were reported at $0. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.
Show as a table
| Year | Hubert Franke | General Practice median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $107 | $37–$285 | $163 |
| 2020 | $0 | $75 | $25–$213 | $114 |
| 2021 | $0 | $93 | $30–$272 | $132 |
| 2022 | $0 | $103 | $36–$279 | $149 |
| 2023 | $16 | $106 | $34–$276 | $160 |
| 2024 | $20 | $114 | $39–$290 | $164 |
| 2025 | $0 | $106 | $35–$292 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 19 billing codesPaid by Medicare
$1,983,218
Medicare patients
746
Services billed
421,928
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Ischemic heart disease | 37% | |
| Diabetes | 36% | |
| Chronic kidney disease | 22% | |
| Atrial fibrillation | 21% | |
| Heart failure | 16% | |
| COPD | 16% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Hyaluronan or derivitive, genvisc 850, for intra-articular injection, 1 mg J7320 | Office | 605 | 132,250 | $555,847 |
| Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml Q9965 | Office | 673 | 214,570 | $253,214 |
| Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg J3304 | Office | 88 | 4,288 | $58,646 |
| Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg J7325 | Office | 56 | 4,064 | $28,380 |
| Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose J7323 | Office | 45 | 221 | $20,285 |
| Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 | Office | 201 | 51,800 | $15,752 |
| Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose J7321 | Office | 23 | 192 | $10,869 |
| Injection, ketorolac tromethamine, per 15 mg J1885 | Office | 460 | 1,605 | $799 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 53 | 340 | $252 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
2 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
General Practice in New Jersey
Practitioners in the same specialty and state, ranked by reported value.
All General Practice
Everyone recorded under this specialty, nationwide.
Doctors in New Jersey
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.